Navigation Links
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Date:4/9/2012

WALTHAM, Mass., April 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin®). The study sponsored by MD Anderson is being conducted in collaboration with the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis and Glaxo Smith Kline (GSK). Preclinical data has demonstrated that entinostat, a novel, selective histone deacetylase inhibitor can overcome acquired resistance to HER2 targeted therapies when combined with lapatinib.

"Based on preclinical work conducted by Syndax's collaborators, GSK scientists and our own laboratory, we believe entinostat may be effective in tackling the resistance pathways that contribute to the reduced efficacy of HER2-targeted agents in breast cancer patients progressing on such therapies," said Naoto T. Ueno, MD, PhD, FACP, Section Chief, Section of the Translational Breast Cancer Research Department of Breast Medical Oncology, Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic, MD Anderson Cancer Center and principal investigator.  "With the data we have generated, we are particularly excited to test this combination in patients with inflammatory breast cancer, a subset of breast cancer often expressing HER2 for whom there are few effective treatment options.

The phase 1 portion of the study will characterize the safety profile of the combination and identify the appropriate dosing regimen to be used in the phase 2 portion. Translational studies will provide valuable insight into the mechanism of action for
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals to Present at BIO Investor Forum
2. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... Ontotext S4 , The Self Service ... Now the same enterprise hardened text mining, Linked ... data is available to start-ups and mid-size businesses at ... that do not have resources to evaluate and prototype ... since there is no need for on premise hardware ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... Clinical Trial Programs Funded Through 2009, SAN ... and Ottawa, Ontario), a clinical stage biopharmaceutical company,developing ... today announced the closing of a financing transaction ... target of $8 million USD.,The offering was completed ...
... 9 InNexus,Biotechnology Inc., (TSX: IXS.V, OTC Bulletin ... commercializing the next,generation of monoclonal antibodies based on ... to its Board of Directors., Mr. Warden ... Coleman, L.L.P.,In his 23 years of practice, he ...
... Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Company"), ... development of novel antibiotics for the treatment ... its,Clinical Advisory Board. The Board, comprised of ... counsel on matters related to the,Company,s clinical ...
Cached Biology Technology:Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 2Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 3InNexus Biotechnology Strengthens Patent Team With New Leadership 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 3
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/20/2014)... John and Rebecca Moores Professor of Biology and Biochemistry at ... the International Society for the Study of the Origin of ... two from the U.S., one from France and one ... elected every three years, and 36 have been named since ... countries, the ISSOL includes researchers from disciplines as varied as ...
(Date:8/20/2014)... Tbingen, Arizona State University, the Wellcome Trust Sanger Institute ... TPH) isolated Mycobacterium pinnipedii from skeletons found ... The pathogen is a relative of the TB bacterium ... humans today. These researchers assume that seals carried the ... to sea lions was unexpected" comments Sebastien Gagneux, from ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2UH professor named fellow by International Astrobiology Society 2
... today at the American College of Neuropsychopharmacology's Annual Meeting ... age 90 with preserved cognition. The study, which ... conducted at the University of Pittsburgh, is among the ... , "While successful aging has been defined in ...
... the world would help stave off an imminent global ... the Proceedings of the National Academy of Sciences ( ... 52 member organizations of the Alliance for Zero Extinction ... threatened with imminent extinction, each of which is in ...
... at the University of Colorado at Boulder that can ... patient samples within hours may help world health officials ... on the new technology by the Centers for Disease ... Chip can determine the genetic make-up of types and ...
Cached Biology News:New research examines genetics of successful aging 2Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 3New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 4
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
...
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
15(S)-HETE-d8 is used as an internal standard for the quantification of 15(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: